CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored
Sandesh Kumar Pattanaik, Diptirani Rath, Amir Mansour Moeini, Mohsen Nabi Afjadi · 2025
Read CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored by Sandesh Kumar Pattanaik, Diptirani Rath, Amir Mansour Moeini, Mohsen Nabi Afjadi (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12661798.txt.
Description
Sandesh Pattanaik, Diptirani Rath, Amir Moeini, and Mohsen Nabi Afjadi published a review in twenty twenty-five on importing cancer's star therapy, engineered CAR T cells, into type 1 diabetes. There the enemy is not a tumor but the immune system's own attack on insulin-producing beta cells, which no current therapy reverses.
The review assembles what is known about retraining T cells to protect, rather than destroy, the pancreatic targets, including regulatory cell variants. Achievements in blood cancers prove the engineering works; diabetes poses different problems of target choice, safety, and durability. The authors catalogue the obstacles honestly and sketch personalized designs as the path forward. A paradigm shift is proposed, not proclaimed, with the unexplored territory clearly marked.
Catalog record
| CREATOR | Sandesh Kumar Pattanaik, Diptirani Rath, Amir Mansour Moeini, Mohsen Nabi Afjadi |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 68 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |